TY - JOUR
T1 - Effect of losartan on serum uric acid in hypertension treated with a diuretic
T2 - The COMFORT study
AU - Matsumura, Kiyoshi
AU - Arima, Hisatomi
AU - Tominaga, Mitsuhiro
AU - Ohtsubo, Toshio
AU - Sasaguri, Toshiyuki
AU - Fujii, Koji
AU - Fukuhara, Masayo
AU - Uezono, Keiko
AU - Morinaga, Yuki
AU - Ohta, Yuko
AU - Otonari, Takatoshi
AU - Kawasaki, Junya
AU - Kato, Isao
AU - Tsuchihashi, Takuya
N1 - Funding Information:
T. T. has received research funding or honoraria from MSD company and Dainippon Sumitomo Pharma Co., Ltd. The authors alone are responsible for the content and writing of the article. This work was supported by the Foundation for Multicenter Clinical Study of the Japan Heart Foundation.
Publisher Copyright:
© 2014 Informa Healthcare USA, Inc. All rights reserved: reproduction in whole or part not permitted.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - It has been shown that losartan, an angiotensin II receptor blocker (ARB), reduces serum uric acid levels. However, the effects of losartan on serum uric acid levels in the patients treated with a thiazide diuretic have not been fully elucidated. We have investigated the effects of losartan compared with other ARBs on blood variables and blood pressure control in hypertensive patients treated with a thiazide diuretic using data from the COMFORT study. The present analysis included a total of 118 hypertensive subjects on combination treatment with ARBs except for losartan and a diuretic who were randomly assigned to a daily regimen of a combination pill (losartan 50 mg/hydrochlorothiazide 12.5 mg) or to continuation of two pills, an ARB except for losartan and a diuretic. Blood pressures were evaluated at 1, 3, and 6 months after randomization and changes in blood variables including serum uric acid were evaluated during 6 months treatment period. Mean follow-up blood pressure levels were not different between the combination pill (losartan treatment) group and the control (ARBs except for losartan) group. On the other hand, serum uric acid significantly decreased in the combination pill group compared with the control group (-0.44 versus + 0.10 mg/dl; p=0.01), although hematocrit, serum creatinine, sodium and potassium were not different between the groups. These results suggest that the treatment regimen switched from a combination therapy of ARBs except for losartan and a diuretic to a combination pill (losartan/ hydrochlorothiazide) decreases serum uric acid without affecting blood pressure control.
AB - It has been shown that losartan, an angiotensin II receptor blocker (ARB), reduces serum uric acid levels. However, the effects of losartan on serum uric acid levels in the patients treated with a thiazide diuretic have not been fully elucidated. We have investigated the effects of losartan compared with other ARBs on blood variables and blood pressure control in hypertensive patients treated with a thiazide diuretic using data from the COMFORT study. The present analysis included a total of 118 hypertensive subjects on combination treatment with ARBs except for losartan and a diuretic who were randomly assigned to a daily regimen of a combination pill (losartan 50 mg/hydrochlorothiazide 12.5 mg) or to continuation of two pills, an ARB except for losartan and a diuretic. Blood pressures were evaluated at 1, 3, and 6 months after randomization and changes in blood variables including serum uric acid were evaluated during 6 months treatment period. Mean follow-up blood pressure levels were not different between the combination pill (losartan treatment) group and the control (ARBs except for losartan) group. On the other hand, serum uric acid significantly decreased in the combination pill group compared with the control group (-0.44 versus + 0.10 mg/dl; p=0.01), although hematocrit, serum creatinine, sodium and potassium were not different between the groups. These results suggest that the treatment regimen switched from a combination therapy of ARBs except for losartan and a diuretic to a combination pill (losartan/ hydrochlorothiazide) decreases serum uric acid without affecting blood pressure control.
UR - http://www.scopus.com/inward/record.url?scp=84928017761&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928017761&partnerID=8YFLogxK
U2 - 10.3109/10641963.2014.933968
DO - 10.3109/10641963.2014.933968
M3 - Article
C2 - 25051056
AN - SCOPUS:84928017761
VL - 37
SP - 192
EP - 196
JO - Clinical and Experimental Hypertension
JF - Clinical and Experimental Hypertension
SN - 1064-1963
IS - 3
ER -